NCT05298007

Brief Summary

To investigate the intervention effect of high definition transcranial direct current stimulation (HD-tDCS) on anxiety symptoms and somatic symptoms in patients with anxiety disorder and its underlying neural mechanism by MRI.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

February 13, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 28, 2022

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

April 6, 2022

Status Verified

March 1, 2022

Enrollment Period

5 years

First QC Date

February 13, 2022

Last Update Submit

March 26, 2022

Conditions

Keywords

Transcranial Direct Current StimulationAnxietyMagnetic Resonance Imaging

Outcome Measures

Primary Outcomes (2)

  • anxiety symptoms

    the change of anxiety symptoms assessed by HAMA scale(Hamilton Anxiety Scale) will constitute the major research outcome measure, to assess response to dDCS. HAMA scale scores range from 0 to 56 points, the higher the score indicates the more serious anxiety symptoms

    baseline and immediately after intervention

  • resting-state functional connectivity

    the change of resting-state functional connectivity strength between stimulated target and the whole brain areas will be measured by functional MRI.

    baseline and immediately after intervention

Secondary Outcomes (5)

  • somatic symptoms

    baseline and immediately after intervention

  • ISI(The insomnia severity index)

    baseline and immediately after intervention

  • SAS(Self-rating anxiety scale)

    baseline and immediately after intervention

  • 4DSQ-Som(Four-DimensionalSymptomQuestionnaire)

    baseline and immediately after intervention

  • HAMD(Hamilton Depression Scale)

    baseline and immediately after intervention

Study Arms (2)

real stimulation

ACTIVE COMPARATOR

Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.

Device: High definition transcranial direct current stimulation

sham stimulation

SHAM COMPARATOR

Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.

Device: sham high definition transcranial direct current stimulation

Interventions

tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.

real stimulation

Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.

sham stimulation

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for anxiety, and HAMA\>14, PHQ-15\>5.
  • the age ranged from 18 to 60 years old, and the length of education was more than 5 years.
  • the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests.

You may not qualify if:

  • accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on.
  • accompanied by other neurological diseases, such as stroke, epilepsy and so on.
  • pregnant and lactating women.
  • accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective disorder, hysteria, autism and so on.
  • patients with MRI taboos or factors affecting imaging quality, such as cardiac pacemaker, cochlear implant, cardio-cerebrovascular metal stent, metal denture, etc.
  • those who could not cooperate with those who completed the relevant experiments, such as patients with depressive stupor, claustrophobia and so on.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anhui Medical University

Hefei, China

RECRUITING

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • Ting Zhang

    Anhui Medical University

    STUDY CHAIR

Central Study Contacts

Yanghua Tian, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of medical psychological department, Anhui Medical University

Study Record Dates

First Submitted

February 13, 2022

First Posted

March 28, 2022

Study Start

January 1, 2021

Primary Completion

December 30, 2025

Study Completion

December 30, 2025

Last Updated

April 6, 2022

Record last verified: 2022-03

Locations